KLI

Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer

Metadata Downloads
Abstract
Purpose The primary objective of our study was to investigate the effectiveness and safety of olaparib maintenance therapy in patients with BRCA-mutated recurrent ovarian cancer in daily practice. The secondary objective of this study was to identify prognostic factors associated with prolonged progression-free survival (PFS) in such patients.

Methods We conducted a retrospective analysis of 40 patients who received olaparib maintenance treatment. Data on clinicopathological factors, oncological outcomes, and adverse events were obtained from medical records and analyzed.

Results All patients had high-grade serous recurrent ovarian cancer with BRCA mutation and achieved complete or partial response to the most recent platinum-based chemotherapy. After a median follow-up of 14.3 months, the median PFS was 23.7 months (95% confidence interval, 14.1-33.4); however, the median overall survival was not reached. In the log-rank test, the PFS was significantly longer for patients with most recent platinum-free interval (PFI) = 12 months, complete response to the last platinum-based chemotherapy, and less than three lines of previous chemotherapy (p = 0.005, p = 0.016, and p = 0.023, respectively). Most hematologic and non-hematologic adverse events were of grade 1 or 2, and the common adverse events were mostly related to myelosuppression.

Conclusion Olaparib maintenance treatment in BRCA-mutated recurrent ovarian cancer is effective and safe in clinical practice. Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.
Author(s)
박정열조안젤라이신화김대연서대식김종혁김용만김영탁
Issued Date
2021
Type
Article
Keyword
BRCA mutationMaintenance therapyOlaparibOvarian cancer
DOI
10.1007/s00404-021-06013-x
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7510
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2515074568&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Real-world%20experience%20of%20olaparib%20as%20maintenance%20therapy%20in%20BRCA-mutated%20recurrent%20ovarian%20cance&offset=0&pcAvailability=true
Publisher
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
Location
독일
Language
영어
ISSN
0932-0067
Citation Volume
304
Citation Number
4
Citation Start Page
1055
Citation End Page
1063
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.